Curanex Pharmaceuticals (CURX) Registration Filing summary

Company overview and business model

• Focuses on discovering, developing, and commercializing innovative botanical drugs for inflammatory diseases, leveraging a proprietary platform for identifying and optimizing anti-inflammatory compounds from medicinal plants.

• Lead candidate, Phyto-N, targets multiple indications including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, gout, and acne, with all research to date in preclinical stages.

• Revenue model anticipates future income from product sales, collaborations, licensing, and research grants, with initial commercialization plans focused on the U.S. and potential strategic partnerships for global markets.

• Acquired IP assets and preclinical data from Duraviva Pharma Inc., including four provisional patent applications and eight animal studies.

Financial performance and metrics

• No revenue generated in 2023 or 2024 due to the strategic shift to pharmaceutical R&D; reported net loss of $(361,506) for 2024, up from $(19,198) in 2023, driven by increased G&A, IPO costs, and impairment charges.

• Cash and cash equivalents as of December 31, 2024, were $148,891, bolstered by a $730,000 asset purchase from Duraviva and a $200,000 loan from a founder.

• Operating cash outflow was $(555,575) in 2024, with $630,100 provided by financing activities.

• Going concern disclosure included, but management believes recent financing and anticipated IPO proceeds alleviate substantial doubt.

Use of proceeds and capital allocation

• Estimated net proceeds of $8 million (or $9.34 million if over-allotment is exercised) at a $5.00/share IPO price.

• Proceeds allocated as follows: $2M for GLP toxicology and pharmacokinetic studies, $1M for clinical trial material manufacturing, $3M for Phase I clinical trial in ulcerative colitis, and $1.96M for working capital and general purposes.

• Full business plan through FDA approval and product launch estimated to require over $150 million, with future phases dependent on additional fundraising.